Tunnel Vision - Senior Scientist bei Bit Bio: Mitarbeiterbewertung

2.0
5. Juni 2024
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Driven and Friendly People: The team at bit.bio consists of highly motivated individuals who are not only focused on achieving their goals but also foster a supportive and friendly work environment. This creates a positive and collaborative atmosphere. Genuine Friendships: Working at bit.bio offers the opportunity to form real and lasting friendships. The company culture encourages personal connections, making it easy to bond with colleagues both inside and outside of work. Investment in New Technology: bit.bio is committed to staying at the forefront of technological advancements. The company's ongoing investment in cutting-edge technology ensures that employees have access to the latest tools and resources to excel in their roles. Innovation: bit.bio thrives on innovation, consistently seeking out new and creative ways to improve its services and products. Employees are encouraged to think outside the box and contribute to the company's innovative initiatives, making it an exciting place to work.

Kontras

High Risk on Clinical Product: The company places all its eggs in one basket with its clinical product, which may not ultimately work. This single-product focus increases uncertainty and potential instability. Additionally, there is a tunnel vision approach, which limits exploration of other potentially viable opportunities. Job Security Concerns: As a start-up/scale-up company, bit.bio faces yearly risks related to job security. There are recurring issues with securing funding, and the company does not invest or put enough focus on revenue generation despite having a good product. Clear Financial Mismanagement Deteriorating Culture: The company culture has significantly declined. While culture was a priority at first, bit.bio now harbors a toxic environment where politics permeate all areas. There is a notable lack of compassion and respect for staff. Limited Career Progression: Career progression opportunities are limited. HR's use of vague, benchmarked frameworks for career advancement creates a sense of gaslighting among the team, as these frameworks are not specific to job roles.

avatar
Reaktion von Bit Bio
1y
Thank you for taking the time to share your feedback. We are sorry to hear about your experience and appreciate your candour. We strive to create a positive and supportive environment for all our employees. Your concerns about financial management, company culture, job security, and career progression are important to us. We take such feedback seriously and are committed to continuous improvement. Our Career Framework is based on the AON Radford Framework which benchmarks rewards, assesses plan design practices and monitor workforce trends across 23.3+ million employees working in 109 countries and is specific to Life Sciences and the scientific framework. As with all start up businesses, there are financial uncertainties, but with the reputation of our ET and Board, bit.bio is in a strong place to prosper. If you would like to discuss your concerns in more detail, please reach out to us directly. We value your perspective and would like to better understand your experience to ensure we are addressing these issues effectively.

Mehr Bewertungen zu Bit Bio entdecken

1.0
13. Aug. 2025
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Many scientists are highly skilled and dedicated to their work and most facilities are well-equipped

Kontras

bit.bio used to be a good company with a strong mission, but the recent leadership changes have made it clear there is no stable strategy or direction. In just two months, the company went through three different CEOs — even governments don’t rotate leaders that fast. In both 2024 and 2025, roughly 20–30% of the workforce was made redundant. These cuts were followed almost immediately by hiring sprees and promotions at senior management level, which made little sense. Internal roles were often tailored to people already chosen to stay, and redundancy packages were inconsistent. What’s worse, company documents from as far back as November 2023 indicated financial instability, yet new hires were still brought on — some only to be let go within weeks or months. Promotions are almost exclusively for senior-level staff; research assistants, even those with 3–6 years of experience, remain stuck in the same role without salary reviews, and requests for progression are met with vague, dismissive explanations. The lack of strategic clarity is striking. For example, in 2024 the company invested in building a cell therapies department, only to make the entire team redundant within months, then shifted focus to commercial hiring, and now seems to be exploring media component development. The result is a constant feeling of uncertainty: offices are half-empty, morale is low, and employees feel undervalued. HR has also not helped the situation — redundancies were handled with minimal transparency and support, with packages kept to the bare minimum. Overall, bit.bio has gone from a place with real potential to one marked by instability, unclear priorities, and poor treatment of staff.

5
avatar
Reaktion von Bit Bio
9mo
Thank you for taking the time to share your feedback. We’re glad you highlighted the dedication and expertise of our scientific teams and the strength of our facilities — these remain some of our greatest assets. We also want to acknowledge your concerns regarding leadership transitions and organisational changes. The past two years have been a very challenging time across the biotech sector, with many companies facing closures or significant restructuring. At bit.bio, we have had to make difficult decisions to secure the company’s future and focus resources where they will have the greatest long-term impact. Regarding redundancies, it is important to clarify that while HR plays a supporting role, these decisions are made at the executive level. HR’s responsibility is to ensure the process is carried out fairly, respectfully, and with support for those affected. These processes were conducted with transparency, and as much detail as could be shared at the time was communicated directly by the Executive team. Given the financial status of the organisation, we were unable to provide enhanced packages, but all statutory requirements were met. In addition, we offered LinkedIn learning training, CV and interview support, and proactively shared CVs with other organisations to help colleagues transition into new opportunities. We understand the impact such changes have on morale and on individuals personally. While these steps cannot take away the difficulty of redundancies, they reflect our commitment to supporting colleagues as best we can under the circumstances. bit.bio remains deeply committed to its mission of accelerating biomedical innovation through cell coding technology, and we continue to focus on building a sustainable path forward where employees feel valued and supported.
4.0
30. März 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

A growth company with fast paced environment bringing good exposure.

Kontras

High volatility based on the funding environment

avatar
Reaktion von Bit Bio
2mo
Thank you for your feedback. We're glad to hear that you’ve found value in the fast-paced, growth-oriented environment at bit.bio and the exposure it provides. We also appreciate your perspective on the challenges related to volatility in the funding environment. While this has been a factor in the past, we have since secured additional funding, which puts us in a more stable position. That said, we remain mindful of the responsibility that comes with this and are focused on deploying it thoughtfully to support our long-term goals and the sustainability of the business.
Bewertungen anzeigen nach: Hilfreich|Sterne|Datum|Alle